Agricultural biologicals have entered a new technology race stretching from the United States to Brazil, according to a report from AgroLatam, as developers push RNA-based crop protection and biocontrol products toward commercial scale in two of the world's most consequential input markets.

The report frames the development as a competitive sprint rather than a steady category build. RNA-based crop protection — an approach that targets specific pests by interfering with their gene expression — and conventional biocontrol products are advancing in parallel on both sides of the equator, with U.S. and Brazilian developers each staking claims to the next generation of agricultural inputs.

Why does this matter for field decisions? Biologicals sit at the intersection of two pressures farmers already manage: tightening chemical options as resistance builds and pesticide active ingredients face regulatory review, and demand from buyers for measurable reductions in conventional pesticide residues. Products that deliver reliable control at commercial scale would give growers a tool that fits both constraints.

Brazil's role in the race is structural. The country is one of the largest users of biological crop protection in the world, driven by tropical pest and disease pressure across soybean, corn and cotton acreage, and by a regulatory pathway that has approved biological products faster than many jurisdictions. That combination makes Brazil a proving ground: products that perform under Brazilian field conditions and at Brazilian application volumes face a demanding test of efficacy and economics.

The U.S. side of the race brings a different advantage. American developers have concentrated on the underlying platform technology — including RNA interference — where precision targeting of specific pests could reduce the broad-spectrum chemistry growers now depend on. The question for U.S. adoption is whether the economics of formulation, stability and application can reach a cost per hectare that competes with established insecticides on row crops rather than only on high-value specialty crops.

For growers, the practical significance of a two-market race is speed. Parallel development in the U.S. and Brazil shortens the feedback loop between trial results and commercial formulation. A product that succeeds in Brazilian soybean fields generates performance data that U.S. growers and their advisers can evaluate; a U.S. platform advance can move into Brazilian trials where pest pressure tests it hardest.

The competitive dynamic also matters for pricing. When multiple developers race to market in the same category, first adopters typically see faster price competition and clearer performance benchmarks than in categories dominated by a single supplier.

AgroLatam's framing of the race from the U.S. to Brazil signals that the biologicals category has moved past the proof-of-concept stage into a contest over market position at scale.

Farmers and crop advisers should watch for regulatory submissions and trial results from both markets in the coming seasons — approvals in Brazil and U.S. field data on RNA-based products will indicate how quickly these tools move from technology race to practical, priced options in the sprayer.